10-K annual report · filed Nov 19, 2026

Azenta, Inc. (AZTA) FY2026 10-K Annual Report

Short answer

Azenta, Inc. (AZTA) filed its fiscal 2026 10-K annual report with the SEC on Nov 19, 2026. It reported revenue of $622M (+4.7% year over year) and net income of −$167M.

  • Top risk flagged: BIOSECURE Act restrictions, including BGI- or MGI-related platforms, could constrain China-based genomic services and supplier access

FY2026 key financial metrics · XBRL

Revenue
$622M
+4.7% YoY
Net income
−$167M
−199.5% YoY
Operating margin
-28.1%
−23.6 pp YoY
Gross margin
44.2%
−1.3 pp YoY
EPS (diluted)
−$3.70
−203.3% YoY
ROE
-12.0%
−8.7 pp YoY
Operating cash flow
$58M
−20.3% YoY

Source: XBRL data from the Azenta, Inc. (AZTA) FY2026 10-K on SEC EDGAR. USD.

Azenta, Inc. FY2026 10-K analysis

AI summary of each section, grounded in the filing text

Business Overview

  • Core model: Life sciences sample management and multiomics solutions spanning storage, genomics, consumables, informatics and repository services
  • New emphasis: SynPlexity acquisition and Elegen license expanding multiplexed gene libraries and cell-free DNA synthesis
  • Strategic shift: B Medical Systems divestiture for $63.0 million, sharpening focus on Sample Management Solutions and Multiomics
  • Restructuring: Three North American Multiomics laboratories slated for closure, targeting approximately $11.0 million annualized savings
  • Scale: Approximately 2,850 workers, 11,000 customers, sales in approximately 87 countries and 12 genomic laboratories globally

Management Discussion & Analysis

  • Revenue $621.7M, up 4.7% YoY from $593.8M, driven by SMS and Multiomics growth
  • Gross margin 44.2% vs 45.5%; operating loss $174.7M vs $26.8M, including $149.1M goodwill impairment
  • Best segment SMS: revenue $344.4M, adjusted operating income $25.2M; worst Multiomics: adjusted operating loss $15.4M
  • Operating cash flow $57.5M; capex $30.1M; share repurchases $118.3M; no dividends planned
  • Fiscal 2027 risks: declining Sanger revenue, constrained capital spending, tariffs, lower interest income, and $11.0M to $13.0M restructuring charges

Risk Factors

  • BIOSECURE Act restrictions, including BGI- or MGI-related platforms, could constrain China-based genomic services and supplier access
  • China exposure: $74.4 million revenue and $177.4 million foreign-currency cash in fiscal 2026
  • Sole- or limited-source suppliers for cryogenic systems, consumables and genomic services create disruption risk
  • AI-enabled discovery and autonomous laboratories could reduce physical testing demand and intensify competition
  • CEO resignation on August 22, 2026, leaves a director as Interim CEO during permanent successor search

Generated from the filing text; verify against the original. How to read a 10-K

Other Azenta, Inc. annual reports

Ask about this 10-K

Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.